OR WAIT null SECS
Kenny Walter is an editor with HCPLive. Prior to joining MJH Life Sciences in 2019, he worked as a digital reporter covering nanotechnology, life sciences, material science and more with R&D Magazine. He graduated with a degree in journalism from Temple University in 2008 and began his career as a local reporter for a chain of weekly newspapers based on the Jersey shore. When not working, he enjoys going to the beach and enjoying the shore in the summer and watching North Carolina Tar Heel basketball in the winter.
Several companies are testing live microbiota therapies for C difficile infections.
There may soon be new treatments available for clostridium difficile infections (CDI) in the form of live microbiota treatments.
With the clinical success of fecal microbiota transplantation (FMT) as a therapy for recurrent CDI as the basis, several companies are readying their own version of live microbiota treatments, some of which are already in later phase trials.
In an interview with HCPLive®, Kerri Glassner, DO, Assistant Professor of Clinical Medicine, Academic Institute, Houston Methodist, explained the excitement behind these therapies and why they might transform C difficile care in the coming years.
“These are coming, these are on the horizon,” Glassner said. “We’re really close to some of these being approved in the near future.”
Glassner recently took part in HCPLive’s State of the Science event chaired by Bincy Abraham, MD, MS, Houston Methodist, called Institutional Perspectives in Infectious Diseases: Management of C. Difficile on November 9th.
Glassner presentation was specifically about emergent treatment options for C difficile infections, which included fecal microbiota transplantation and the new microbiota biotherapeutics in clinical trials.
“There’s really a lot of excitement with these newly emerging options,” she said. “These really open the door for the manipulation of the microbiome, which can be used to treat a whole host of different other conditions.”